Date: 2017-06-21
Type of information: Private placement
Company: Clovis Oncology (USA - CO)
Investors:
Amount: $300 million
Funding type: private placement
Planned used:
- Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib) in the United States and, if approved by the European Medicines Agency (EMA), in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.
Others:
- • On June 21, 2017, Clovis Oncology announced that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares. The offering, including the sale of the additional shares, is expected to close on June 26, 2017, subject to customary closing conditions.
- • On June 20, 2017, Clovis Oncology announced the pricing of the underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $250 million to $300 million. In addition, the underwriters have a 30-day option to purchase up to an additional 511,363 shares of common stock from Clovis Oncology on the same terms and conditions.
- • On June 19, 2017, Clovis Oncology announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. J. P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. Stifel and SunTrust Robinson Humphrey are acting as co-managers for the offering.
- In addition, Clovis Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Cancer - Oncology
Is general: Yes
